Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcabene for the Treatment of Pediatric NAFLD: A Phase 2a Study

Trial Profile

Gemcabene for the Treatment of Pediatric NAFLD: A Phase 2a Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2018

At a glance

  • Drugs Gemcabene (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Aug 2018 According to Gemphire Therapeutics media release, this trial was terminated due to unexpected liver problems observed in the patients that underwent 12-week MRI-PDFF imaging scans.
    • 10 Aug 2018 According to Gemphire Therapeutics media release, the Data and Safety Monitoring Board (DSMB) at Emory University School of Medicine overseeing this trial has recommended that the trial be terminated due to unanticipated problems.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top